ArticleLaryngoscope investigative otolaryngology2025
Impact of Anticoagulation Therapy on Healthcare Utilization in Patients With Epistaxis.
Article in Laryngoscope investigative otolaryngology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of Anticoagulation Therapy on Healthcare Utilization in Patients With Epistaxis.Laryngoscope investigative otolaryngology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Epistaxis can occur in individuals on anticoagulants, raising concerns about the potential impact on healthcare utilization. This retrospective analysis aims to compare measures of healthcare utilization of two cohorts: adult epistaxis patients without anticoagulant use compared to adult epistaxis patients on anticoagulants. Methods: A retrospective analysis using TriNetX datasets from 2014 to 2024 compared the outcomes of two cohorts: cohort 1 (18,550 patients) named "Epistaxis without Anticoagulation > 18 years" and cohort 2 (9530 patients) named "Epistaxis with Anticoagulation > 18 years". The populations were matched for demographics, leaving 5480 in each cohort. The following outcomes were measured: subsequent hospital care, Emergency Department (ED) services, hospital observation services, diagnostic radiology procedures of the chest, surgical procedures on the respiratory system, surgical procedures on accessory sinuses, and post-op control of nasal hemorrhage posterior or anterior. Results: Analyses show Cohort 2 at an increased risk for subsequent hospital care (RR 5.99 [4.31-8.33]), ED services (RR 2.70 [2.39-3.03]), hospital observation services (RR 3.00 [1.81-4.98]), and diagnostic radiology procedures of the chest (RR 3.92 [3.25-4.74]). There was a significant increase in the number of ED services required by cohort 2 ( Conclusion: This analysis highlights the potential impact of anticoagulation therapy on healthcare utilization in the management of epistaxis and underscores the importance of careful monitoring and appropriate management strategies for this patient population. Level of Evidence: IV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.